Are you at risk for colorectal cancer? Answer these 13 questions in less than 1 minute to find out.
Our Clinical Trial Finder is a one-stop place to find and learn more about high-impact research studies for patients with advanced CRC. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status.
Our Path to a Cure report is our plan for the future. This plan is not just for Fight CRC, but for everyone who is willing to champion this cause.
Shop our online store to raise awareness everywhere you go! From t-shirts and fanny packs to patient education resources, we have a little bit of everything.
Raise Awareness. Be an Advocate. Host an Event.
Program Status Clinical trial’s patient recruitment status
Phase Phase of the clinical trial that is recruiting (I, II, or III)
Immunotherapy-centered Trial A flag to indicate whether the trial is an immunotherapy trial
Prior Immunotherapy Allowed Whether the clinical trial is open to patients who have received prior immunotherapy
CRC-directed Trial A flag to indicate whether the trial is specifically targeting colon cancer, rectal cancer, or colorectal cancer patients
Drugs Therapeutics used in the clinical trial
Tags
Comments
Key inclusion/ exclusion criteria: patient needs to have a KRAS p.G12C mutation. October 2019: one CRC patient response. See Helpful Links Even if not exclusive for CRC, important, given the specific targeting of the mutation. Other trial targeting KRAS G12C: NCT03600883 Update: combination arm with cetuximab. Update 2022: has results. “32 patients with CRC cancer with the KRASG12C mutation were treated with adagrasib and cetuximab. The ORR was 46% among 28 evaluable patients and DCR was 100%, and median PFS was 6.9 month (median prior lines of systemic therapy was 3)”.
Helpful Links
Contacts
Inclusion Criteria
Inclusion Criteria:
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation Unresectable or metastatic disease Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts Adequate organ function
Exclusion Criteria
Exclusion Criteria:
History of intestinal disease or major gastric surgery or inability to swallow oral medications Other active cancer
NCT ID Trial ID number from clinicaltrials.gov or other database
Date Trial Added Date on which the clinical trial was added to the clinicaltrials.gov website
Updated Date Date on which the clinical trial was updated on the clinicaltrials.gov website